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.2012.11Abstract Asthma is a chronic, reversible obstructive disease that when in exacerbation can present
to the emergency department in a spectrum of severity. Prompt recognition of the potentially
severely ill asthmatic requires a careful history and physical exam while considering alternative
diagnoses for the presenting symptoms. Early administration of salbutamol and corticosteroids is
indicated in almost all patients with other medications such as ipratropium and magnesium and
supportive modalities like BiPAP reserved for sicker patients. The global impact of asthma is
increasing, especially amongst children. While the benign clinical presentation is most common
and mortality has decreased in recent decades due to improved recognition and care, the ubiquity
of the condition and frequent lack of regular outpatient management contribute to the disease
claiming 250,000 lives worldwide annually. The emergency physician must be prepared to assess
and appropriately manage both the young child with a mild wheeze and the adult in respiratory
failure.
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HelioxAbstract L’asthme est une maladie chronique et re´versible qui, en cas d’aggravation, peut faire
l’objet de visites au service des urgences a` diffe´rents degre´s de gravite´. L’identiﬁcation rapide de
l’asthmatique potentiellement tre`s malade ne´cessite un examen soigne´ des ante´ce´dents me´dicaux
et physiques et la prise en conside´ration de diagnostics alternatifs quant aux symptoˆmes pre´sente´s.
L’administration pre´coce de salbutamol et de corticoste´roı¨des est indique´e pour la quasi-totalite´ des
patients sous traitement diffe´rent, comme l’ipratropium et le magne´sium, et utilisant des modalite´s
de traitements comme le BiPAP pour les patients plus gravement malades. L’impact global de
l’asthme augmente, notamment chez les enfants. Si la maladie se pre´sente le plus souvent sous forme
be´nigne et si la mortalite´ a diminue´ au cours de ces dernie`res de´cennies graˆce a` une meilleure iden-
tiﬁcation et une meilleure prise en charge, l’ubiquite´ de cette maladie et l’absence fre´quente de prise
en charge re´gulie`re des patients externes contribue au de´ce`s attribuable a` la maladie de 250 000 per-
sonnes par an dans le monde. Le me´decin d’urgence doit eˆtre pre´pare´ a` e´valuer et ge´rer comme il se
doit le jeune enfant pre´sentant un le´ger sifﬂement comme l’adulte en de´tresse respiratoire.
ª 2013 Production and hosting by Elsevier on behalf of African Federation for Emergency Medicine.Introduction
Asthma is a chronic reversible inﬂammatory condition
affecting the lower airways, most prevalent amongst children
and adolescents. Clinical presentation can range from mild
wheezing, cough, or chest tightness to severe respiratory
distress or respiratory failure. Prompt recognition and
administration of medications are critical for effective
management.Epidemiology
Asthma affects approximately 300 million people worldwide.1
While typically thought of as a disease of urban centres in
North America and Europe, asthma has a signiﬁcant and
growing impact on health throughout Africa. Although
available data to evaluate trends in Africa are limited2, a re-
cently published review of the available literature suggests that
prevalence is rising throughout sub-Saharan Africa, with rates
from 5.7% to 20.3%, and highest in urban areas.3 While lack
of standardized reporting in most of the rest of Africa prevents
proper comparison, South Africa’s mortality rate of 18.5/
100,000 asthmatics ranks ﬁfth-highest in the world.1 As more
Africans adopt western lifestyles and move to urban centres,
the current estimate of close to 50 million asthmatics living
on the continent is expected to grow.1Pathophysiology
Asthma is a chronic, reversible obstructive disease of the lower
airways. Constriction of bronchial smooth muscle in acute
attacks leads to the characteristic wheezing associated with
asthma. In addition to bronchospasm, inﬂammation causing
microvascular leakage and airway oedema leads to further air-
way narrowing.
The pathophysiologic changes in an asthma exacerbation
involve multiple inﬂammatory cells and mediators. Allergens
activate mast cells through an IgE-mediated pathway, caus-ing release of bronchconstrictor mediators.4 Similar release
occurs in a non-IgE-mediated pathway secondary to cold
exposure, exercise5, and medications such as NSAIDs or
aspirin.6 The release of speciﬁc chemokines and cytokines
from inﬂammatory cells promotes further local inﬂammatory
change.7,8Initial evaluation
Formal diagnosis of asthma is based upon pulmonary function
testing, but the diagnosis is made on clinical grounds in the
acute setting. Episodic wheezing, shortness of breath, chest
tightness, and cough are clinical hallmarks although any com-
bination of these symptoms is possible. The history should in-
clude when the current symptoms started, how they compare
to previous exacerbations, and response to any medications
administered prior to presentation. It is also important to
ascertain the dosage of all current medications, previous hospi-
talizations or intubations for asthma, and the presence of other
cardiac or respiratory disease.
Patients should be placed in an area where monitoring and
frequent re-evaluations can be performed by a staff. Continu-
ous pulse oximetry is indicated in patients that are hypoxic on
arrival or are in severe distress.9 While initial vital signs and
ensuing changes can be a useful marker of clinical status, nor-
mal or near normal vital signs do not exclude the diagnosis of
severe asthma exacerbation.History
Identifying the potentially seriously ill asthmatic is often dif-
ﬁcult, as physical exam ﬁndings indicative of severe airﬂow
obstruction such as use of accessory muscles, diaphoresis,
and inability to lie supine due to breathlessness are not sufﬁ-
ciently sensitive.10 This increases the importance of obtaining
a good history of present illness and thorough past medical
history. Frequency of usage and compliance with home
asthma medications, more than three visits to the emergency
centre in the past year, admission to the hospital ﬂoor or
184 T. Greene et al.ICU in the past month, and previous intubations are
indicators of a patient that could be at risk for acute
decompensation and respiratory failure.11,12 Such consensus
guidelines regarding risk factors have borne out in studies
at African hospitals.13
Physical exam
The physical exam hallmarks in acute asthma exacerbation are
classically wheezing, tachypnoea, respiratory distress, cough,
chest tightness, and accessory muscle use, which can be present
in any combination.14 Monitoring level of consciousness,
respiratory rate, accessory muscle use, and degree of wheezing
are elements of the exam repeated to assess a patient’s clinical
status in response to therapeutics.Testing
While some recommend the use of ABG as a measurement of
respiratory status (speciﬁcally evaluating for hypercarbia in the
severely ill patient potentially failing treatment), common
practice is to make decisions regarding treatment based on
clinical grounds. Peak expiratory ﬂow (PEF) is a quantitative
measure of lung function that when included in a patient’s
assessment is more reliable in assessing severity than clinical
symptoms alone.15 When obtained at presentation, PEF
provides an objective baseline of airway obstruction to com-
pare against following therapeutic intervention. Most
improvement in PEF will be after the ﬁrst treatment with beta
agonists.16
Other blood testing and imaging including chest X-ray are
generally only warranted when alternate diagnoses such as
pneumonia or foreign body are being considered and should
not be part of routine evaluation.17Assessment
Differentiating mild, moderate, and severe asthma exacerba-
tions is done on clinical grounds and, if available, peak expira-
tory ﬂow (PEF). Mild asthma is characterized by moderate
expiratory wheeze, PEF <80% predicted or personal best,
dyspnoea with exertion, and ability to speak in full sentences.
In moderate asthma exacerbations (PEF 60–80%) the patient
has dyspnoea with talking, a loud wheeze and possibly supra-
sternal retractions and accessory muscle use noted on physical
exam. The severe asthma (PEF <60%) patient will commonly
be unable to speak more than words secondary to dyspnoea,
exhibit accessory muscle use, and have marked inspiratory
and expiratory wheezes on auscultation.18 Very poor air move-
ment with or without wheezing (often referred to as a ‘‘silent
chest’’), respiratory muscle fatigue, cyanosis, and altered men-
tal status are ﬁndings concerning for impending respiratory ar-
rest.19 Identifying where a patient falls within this spectrum
can be helpful when considering therapeutic options and likely
disposition.When evaluating paediatric patients there is increasing reli-
ance on the physical exam, as obtaining PEF values in infants
and children under ﬁve years of age (and frequently in older
children) is nearly impossible. In addition to clinical judgment,
pulse oximetry at presentation and after one hour of treatment
in this population can be a useful adjunct to help assess clinical
status.20Differential diagnosis
Following the dictum ‘‘All that wheezes is not asthma,’’ a com-
mon mistake is to not consider other diagnoses in the wheezing
patient. Especially in the paediatric population, upper respira-
tory tract infections can cause lower airway inﬂammation and
clinical wheezing. Neither airﬂow limitation nor airway inﬂam-
mation can be routinely assessed in children under the age of 5,
adding to the difﬁculty of diagnosis in this age group and
increasing the importance of a thorough history.21 While in
adults many patients will carry a known diagnosis of asthma,
in the wheezing paediatric patient further information regard-
ing the frequency of similar symptoms, any known triggers
(such as cockroaches, mites22, mould, pollen, air pollution,
animal dander, and tobacco smoke23), family history, and pre-
vious response to bronchodilators can help differentiate asth-
ma from wheezing associated with viral illness or other
disease processes.14
Other disease processes to consider in the wheezing patient
are COPD, congestive heart failure, pulmonary embolism,
pneumonia, tumours, cough secondary to drugs (ACE inhibi-
tors, etc.), foreign body aspiration, aspiration pneumonitis,
allergic rhinitis, postnasal drip, gastroesophageal reﬂux, and
vocal cord dysfunction.19 The clinical features of COPD and
asthma closely overlap; in the older patient with a reported his-
tory of asthma presenting with acute shortness of breath sus-
pected to be of pulmonary origin a heavy smoking history
and initial onset of symptoms in middle age could suggest
COPD as the underlying aetiology. Even with outpatient pul-
monary function testing the diagnosis often remains unclear,
also many patients have both diseases.24Management
Oxygen
Asthmatic patients can develop hypoxaemia secondary to
ventilation-perfusion mismatch. Any patient with an initial
oxygen saturation of less than 90% should receive supplemen-
tal oxygen, ﬁrst via nasal cannula, reserving non-rebreather
masks for those who remain hypoxaemic on nasal cannula.
Flow should be titrated down to the lowest level required to
maintain the oxygen level above 90%. A target of 95% is
recommended in children, pregnant women, and those with
coexistent heart disease.18
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Effective treatment of the acute asthmatic exacerbation is
predicated on rapid administration of bronchodilators to all
patients. Short-acting beta agonists relieve bronchospasm
and can be given in different forms, via intermittent or contin-
uous nebulization or metered dose inhalers (MDI) with a mask
or mouthpiece. Depending on resources, all are reasonable
treatment options in mild to moderate exacerbations and have
been shown to be equivalent in both paediatric and adult
populations.25 MDIs are favourable in regard to cost and
shorter duration of stay in the emergency centre.26 Homemade
spacers made of soda bottles can be as clinically effective as
commercial spacers, both helping increase the amount of
medication inhaled.27
Salbutamol is the most common beta-2 agonist used for
acute asthma. Dosing of this medication via MDI (90 mcg/
puff) with a spacer device is 4–8 inhalations every 20 min for
up to 4 h. In paediatric patients 4–8 inhalations every 20 min
for three doses, then every 1–4 h. For continuous nebulization,
2.5–5.0 mg of salbutamol (or 0.15 mg/kg in paediatric patients)
is administered every 20 min for 1 h.28 Side effects of salbuta-
mol include tachycardia, tremor, hypokalaemia, palpitations,
and hyperglycaemia.Anticholinergics
Ipratropium has been shown to be an effective adjunct to in-
haled beta agonists in moderate to severe asthma exacerbations.
A muscarinic acetylcholine receptor inhibitor, ipratropium
works to relax vagally-mediated smooth muscle. Due to its slow
onset time (90 min) and lesser potency as a bronchodilator,
ipratropium should never be used as a single agent for acute
asthma. via nebulizer 0.5 mg of ipratropium is given every
20 min for a maximum of three doses. When administering with
a MDI, 8 puffs every 20 min for upwards of 3 h is a standard
regimen. While recommended in all age groups, it has been
found to be especially effective in paediatric populations, help-
ing to decrease hospital admissions by 25% in children.14 There
is no evidence-based role for ipratropium inmild exacerbations,
and if unavailable, most patients can be safely managed with
salbutamol alone in the outpatient, emergency centre, and
inpatient settings.Steroids
The early administration of corticosteroids is recommended in
patients with moderate to severe exacerbations or those pa-
tients not responding quickly or completely to beta2-agonist
therapy. Corticosteroids work to decrease the inﬂammatory
reaction that with bronchospasm characterize acute asthma.
Prednisone is most commonly given; clinical effect is typically
within six hours. Early administration of corticosteroids has
been shown to decrease hospital admission and relapse
rates.29,30 Oral corticosteroids should be continued for 3–
10 days (Prednisone 40–60 mg is typical) following dischargeto decrease the risk of relapse. Depending on availability, pred-
nisolone (1–2 mg/kg for 3–5 days) and hydrocortisone (2–
4 mg/kg) are also appropriate alternatives. Oral and intrave-
nous steroids are equivalent although the intravenous route
is recommended for patients in respiratory failure and others
unable to tolerate medication by mouth.31 Typical dosage
for the critically ill asthmatic is intravenous methylpredniso-
lone 60–80 mg every 12 h.Magnesium
Intravenous magnesium causes bronchodilation by inhibiting
the inﬂux of calcium into cells. This medication is generally re-
served for severe exacerbations and has been shown to de-
crease the rate of hospital admission.32 The standard dose is
2 mg intravenous infused over 20 min.Methylxanthines
Intravenous aminophylline and theophylline as individual
agents are inferior to beta agonists and provide no signiﬁcant
further bronchodilation when given in addition to beta ago-
nists to adult patients and non-critically-ill children.33 Thus
their administration is not recommended as part of standard
treatment for acute asthma exacerbation. In addition to other
standard treatment, intravenous bronchodilators can be con-
sidered in paediatric status asthmaticus patients with impend-
ing respiratory failure, being mindful of their signiﬁcant side
effect proﬁle.34Epinephrine
While in theory it may decrease airway resistance and oedema,
there is insufﬁcient evidence to support the routine use of epi-
nephrine in themanagement of the critically-ill asthmapatient.35
One scenario in which the subcutaneous administration of
epinephrine is recommended is in the prehospital setting
when salbutamol or another short-acting beta2-agonist is
unavailable.14Heliox
The rationale behind the administration of helium–oxygen
mixtures (80:20 or 70:30) in asthmatics is that the low density
of helium decreases turbulent airﬂow, thus allowing for im-
proved ventilation and decreased work of breathing. This
property of helium is also thought to help maximize delivery
of salbutamol to the lung periphery, thereby enhancing bron-
chodilation. Available clinical data regarding efﬁcacy of He-
liox are mixed due to lack of large trials; at this time it
cannot be recommended as a part of the standard management
of the asthmatic patient.36 Heliox-driven nebulization of salbu-
tamol should be considered for severely-ill patients that do not
respond to conventional therapies within one hour.37 Standard
186 T. Greene et al.administration is with the gas mixture set at 8–10 L/min and
double the usual dose of salbutamol.
BiPAP
Commonly used in the management of congestive heart fail-
ure and COPD, non-invasive positive pressure ventilation
has been increasingly utilized in severe asthmatics not
improving with standard therapy. Small trials have shown
decreased rates of hospitalization in adults and also possible
beneﬁt amongst paediatric patients.14,38 A higher quality
study is required before non-invasive positive-pressure venti-
lation (NPPV) becomes part of standard recommended prac-
tice for severe asthmatics but can be considered when the
next step in management for the patient failing medical ther-
apy is intubation.Intubation and mechanical ventilation
The severely ill asthma patient that requires intubation is rare,
but this level of airway management may be required when
other measures fail. Indications include worsening mental sta-
tus, respiratory arrest, or severe hypoxaemia. Ketamine is the
preferred induction agent for rapid sequence intubation for
its bronchodilatory properties.39 Intubation should be a last re-
sort in the asthmatic, as they are often difﬁcult to appropriately
manage on the ventilator. The risk of barotrauma secondary to
auto-PEEP and hyperinﬂation can be minimized by reducing
respiratory rate and tidal volume and increasing exhalation
time by increasing inspiratory ﬂow rate. It is critically impor-
tant to decrease the I:E ratio substantially (3–5 times normal)
in intubated asthma patients to ventilate them safely.Disposition
While the decision is clear in the severely ill asthmatic patient
that requires ICU or other higher level monitoring, for the
moderate exacerbation determining disposition can be difﬁcult
and depends largely on clinical judgment. Factors that suggest
the need for admission include PEF <40% of predicted fol-
lowing treatment, new-onset asthma, multiple previous hospi-
talizations for asthma, use of glucocorticoids at time of
presentation with worsening of symptoms, and complicating
psychosocial factors.
Patients demonstrating rapid improvement following treat-
ment should be observed for at least 30–60 min prior to dis-
charge to monitor for relapse.40 If the decision is made to
discharge a patient, oral glucocorticoids for 3–10 days have
been shown to decrease relapse rate and are generally indicated
in those patients with a severity of illness that necessitated an
emergency centre visit.20Summary
Prompt recognition of the clinical symptoms of asthma and
timely administration of beta-2 agonists and corticosteroids,while under close monitoring considering the need for ipratro-
pium and magnesium are integral to managing the sick asth-
matic patient.African relevance
 Asthma is recognized as having an increasing impact on the
health of Africans, especially in urban areas.
 Early diagnosis and proper management can signiﬁcantly
improve morbidity and mortality while requiring little to
no testing.
 Widely available and currently utilized therapeutics can be
augmented by newer treatment modalities in the care of
the critically ill asthmatic.
What’s new?
 Prompt recognition via history and physical exam of the
severely ill asthmatic patient and timely therapeutic inter-
vention can decrease hospital admission.
 Salbutamol and corticosteroids are the mainstays of treat-
ing acute asthma; magnesium and ipratropium should be
reserved for the moderate to severe exacerbation.
 Emerging therapies including Heliox and BiPAP are poten-
tially useful adjuncts in staving off intubation in the most
critically ill asthma patients.
Appendix A. Short answer questions
Test your understanding of the contents of this original paper
(answers can be found at the end of the regular features
section).
1. A 30-year-old man with a history of asthma presents to the
emergency centre with worsening shortness of breath
refractory to his prescribed salbutamol inhaler. Initial vital
signs include a respiratory rate of 14 and SaO2 of 99%. On
physical exam he is in minimal distress with bilateral expi-
ratory wheezes on auscultation. Your initial management is
to order:
a. an arterial blood gas analysis
b. a chest X-ray
c. salbutamol via nebulization or metered dose inhaler
d. oxygen via nasal cannula
e. BiPap
2. Which medication has been shown to have beneﬁt in mod-
erate and severe asthma but not in the mild exacerbation?
a. Theophylline
b. Magnesium
c. Salbutamol
d. Montelukast
e. Azithromycin
Asthma essentials 1873. The preferred induction agent when intubating the severely
ill asthma patient is:
a. Midazolam
b. Etomidate
c. Thiopental
d. Ketamine
e. Lorazepam
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